| Silk Logistics Holdings Limited (SLH) ORDINARY FULLY PAID |
Industrials |
- |
FY25 Half Year Report
|
27 Feb 2025 8:09AM |
$2.070 |
$2.140 |
risen by
3.38%
|
|
| McMillan Shakespeare Limited (MMS) ORDINARY FULLY PAID |
Industrials |
$1,179 |
1HFY25 Results Market Announcement
|
27 Feb 2025 8:09AM |
$14.060 |
$16.930 |
risen by
20.41%
|
|
MMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory net profit after tax of $45.2 million, up 3.4% on 1HFY24
- Normalized revenue of $267.4 million, up 2.4% on previous year
- Normalized EBITDA declined 7.1% to $80.8 million
- Declared a fully franked dividend of $0.71
- Strong momentum in novated lease sales, up 6.8%
- Oly brand expanded to 312 new employers
- Normalised return on capital employed of 61.7%
- Interim fully franked dividend reflects a 100% payout ratio of normalised UNPATA
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acusensus Limited (ACE) ORDINARY FULLY PAID |
Information Technology |
$261 |
Acusensus 1H FY25 Results Release
|
27 Feb 2025 8:09AM |
$1.240 |
$1.605 |
risen by
29.44%
|
|
ACE - Price-sensitive ASX Announcement
Full Release
Key Points
- Hemi Project is progressing towards construction with expected timeline for first gold production.
- Ongoing environmental assessments are crucial for the project’s approval.
- De Grey Mining Ltd anticipates receiving primary environmental approvals by September 2025.
- The report includes detailed geotechnical and metallurgical analyses.
- Stakeholder engagement is emphasized to align with community and indigenous interests.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$102 |
H1 FY25 Financial Results Release
|
27 Feb 2025 8:09AM |
$0.830 |
$0.670 |
fallen by
19.28%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Group Net Revenue $81.0M, up 6.0% on previous corresponding period.
- Components & Consumables segment $48.9M, up 4.9%.
- Capital Equipment segment $29.9M, up 8.1%.
- Group Normalised EBITDA $7.9M, up 97.2%.
- Operating NPATA of $1.0M.
- Net Debt decreased by $2.3M to $30.6M.
- Guidance maintained for FY25 Net Revenue of $160.0M to $165.0M.
- Customer demand showed strong growth compared to H1FY24.
- Investment in Disruptive Technologies expected to be around $1.0M.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acusensus Limited (ACE) ORDINARY FULLY PAID |
Information Technology |
$261 |
Acusensus Appendix 4D and Half-Year Financial Report
|
27 Feb 2025 8:08AM |
$1.240 |
$1.605 |
risen by
29.44%
|
|
ACE - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss after tax increased by 111.7% to $511,000.
- Revenue increased by 16.4% to $28.8 million.
- New contracts in South Australia and New Zealand contributed to revenue growth.
- Operational expenses rose due to investments for future growth.
- No dividends were declared for the half-year.
- Net tangible assets per share increased from $0.27 to $0.32.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Silk Logistics Holdings Limited (SLH) ORDINARY FULLY PAID |
Industrials |
- |
Appendix 4D
|
27 Feb 2025 8:08AM |
$2.070 |
$2.140 |
risen by
3.38%
|
|
SLH - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 4.1% to $287.873 million.
- Underlying net profit after tax fell by 68.7% to $2.388 million.
- Loss from ordinary activities after tax was $2.146 million.
- No interim dividend declared for the current period.
- Previous interim dividend was 2.82 cents per share.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$102 |
H1 FY25 Appendix 4D and Interim Report
|
27 Feb 2025 8:08AM |
$0.830 |
$0.670 |
fallen by
19.28%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group's revenue for H1 FY25 was $81.0 million, a 6% increase from H1 FY24.
- The company reported a net loss of $3.5 million for the period.
- Strong organic growth was observed in the Components and Consumables segment.
- Trajan emphasizes the importance of reliable analytical data for human health.
- The company has invested significantly in its manufacturing capabilities in Malaysia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| McMillan Shakespeare Limited (MMS) ORDINARY FULLY PAID |
Industrials |
$1,179 |
1HFY25 Results Presentation
|
27 Feb 2025 8:08AM |
$14.060 |
$16.930 |
risen by
20.41%
|
|
MMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue up 2.4% with growth across all segments
- Operating expenses increased to drive customer growth and ongoing efficiencies
- Simply Stronger Program on track
- Benefits realisation to increase in 2HFY25
- Onboard Finance continues to scale, with FY25 being the last year of Normalisation
- Interim dividend is 71c reflecting a 100% payout ratio of Normalised UNPATA
- Normalised EBITDA margin at 30.2%
- High levels of customer satisfaction reflected in Net Promoter Scores
- Recurring revenue constitutes approximately 52% of statutory revenue
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,668 |
HY25 Results - Investor Presentation
|
27 Feb 2025 8:08AM |
$4.020 |
$4.600 |
risen by
14.43%
|
|
MPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Underlying NPAT increased by 13.8% to $298.7 million.
- Interim fully franked dividend of 7.8 cents per share, up 8.3%.
- COVID-19 financial support package of $160 million announced.
- Medibank Health segment profit rose 40.8% to $37.6 million.
- Strong focus on disciplined growth in both resident and non-resident health insurance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austco Healthcare Limited (AHC) ORDINARY FULLY PAID |
Health Care |
$142 |
Austco Healthcare HY Dec 24 Results Media Release
|
27 Feb 2025 8:08AM |
$0.300 |
$0.380 |
risen by
26.67%
|
|
AHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from customers increased by 62% to $36.9 million.
- EBITDA rose by 150% from $2.1 million to $5.2 million.
- Net Profit Before Tax increased by 270% from $1.0 million to $3.9 million.
- Unfilled Contracted Revenue steady at $50.2 million.
- Growth driven by acquisitions and strong organic growth in Asia and North America.
- Company focuses on innovation, product development, and sustainable growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austco Healthcare Limited (AHC) ORDINARY FULLY PAID |
Health Care |
$142 |
Austco Healthcare Appendix 4D and HY Dec 24 Results
|
27 Feb 2025 8:08AM |
$0.300 |
$0.380 |
risen by
26.67%
|
|
AHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue increased by 61.6% to $36.9 million.
- Net profit after tax rose by 150.1% to $2.9 million.
- Successful integration of acquired businesses contributed $11.9 million in revenue.
- Unfilled Contracted Revenue stands at $50.2 million.
- Cash position improved to $14.9 million, debt-free status maintained.
- Research and Development investment remained steady at $2.3 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,668 |
HY25 Results - Media Release
|
27 Feb 2025 8:08AM |
$4.020 |
$4.600 |
risen by
14.43%
|
|
MPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating profit up 10.2% to $349.2 million.
- Medibank Health segment profit increased by 40.8%.
- Underlying net profit after tax rose by 13.8% to $298.7 million.
- Dividend increased to 7.8 cents per share, up 8.3% from the previous year.
- Non-resident policy unit growth of 12.6% driven largely by students.
- Total claims paid reached $3.3 billion.
- $160 million cash give back announced as part of COVID-19 support.
- Customer growth in the resident segment showed an increase of 18,500 policyholders.
- Company continues to invest in health transition and customer care initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Silk Logistics Holdings Limited (SLH) ORDINARY FULLY PAID |
Industrials |
- |
Scheme Update
|
27 Feb 2025 8:08AM |
$2.070 |
$2.140 |
risen by
3.38%
|
|
| McMillan Shakespeare Limited (MMS) ORDINARY FULLY PAID |
Industrials |
$1,179 |
Appendix 4D and Half Year Report
|
27 Feb 2025 8:07AM |
$14.060 |
$16.930 |
risen by
20.41%
|
|
MMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations rose by 7.9% to $276,829,000.
- Net profit after tax attributable to members was $45,224,000.
- Interim dividend declared at 71 cents per share.
- No significant changes in the nature of activities during the period.
- The Simply Stronger program aims to enhance digital experiences and operational efficiencies.
- Normalised UNPATA from continuing operations was $49,634,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,668 |
Dividend/Distribution - MPL
|
27 Feb 2025 8:07AM |
$4.020 |
$4.600 |
risen by
14.43%
|
|
| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$50 |
Update - Notification of buy-back - GTN
|
27 Feb 2025 8:07AM |
$0.535 |
$0.260 |
fallen by
51.40%
|
|
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$1,495 |
Update - Notification of buy-back - MGH
|
27 Feb 2025 8:07AM |
$3.850 |
$4.110 |
risen by
6.75%
|
|
| Vitura Health Limited (VIT) ORDINARY FULLY PAID |
Health Care |
$38 |
Change of Director's Interest Notice
|
27 Feb 2025 8:07AM |
$0.087 |
$0.057 |
fallen by
34.48%
|
|
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,668 |
HY25 Results - Appendix 4D and Financial Report
|
27 Feb 2025 8:07AM |
$4.020 |
$4.600 |
risen by
14.43%
|
|
MPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Group operating profit increased by 12.7% to $360.1 million.
- Health insurance revenue rose by 5.0% to $4,113.9 million.
- Net profit after tax attributable to shareholders decreased by 0.8% to $340.3 million.
- Interim dividend declared at 7.8 cents per share.
- Strong performance in the Medibank Health segment with a 40.8% profit increase.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$616 |
FY24 Results Investor Presentation
|
27 Feb 2025 8:07AM |
$1.460 |
$1.920 |
risen by
31.51%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor's technology enables cardiac procedures without ionizing radiation.
- Revenue of US $959k in FY2024, up 56% from the previous year.
- The company is the only one globally with MRI-compatible devices for cardiac procedures.
- Imricor's products are approved in 31 countries, with growth expected in several markets.
- The NorthStar 3D Mapping System is critical for the future of iCMR labs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,671 |
Net Tangible Asset Backing
|
27 Feb 2025 8:07AM |
$2.740 |
$4.220 |
risen by
54.01%
|
|
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,539 |
Dividend/Distribution - IEL
|
27 Feb 2025 8:07AM |
$11.790 |
$5.530 |
fallen by
53.10%
|
|
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,668 |
Medibank to return $160m to customers
|
27 Feb 2025 8:07AM |
$4.020 |
$4.600 |
risen by
14.43%
|
|
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,539 |
H1 FY25 Investor Presentation
|
27 Feb 2025 8:07AM |
$11.790 |
$5.530 |
fallen by
53.10%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue of A$475.4 million down 16%
- Adjusted EBIT of A$92.7 million down 40%
- Student Placement volumes down 15%
- English Language Testing volumes down 19%
- Overhead costs reduced by 14%
- GOCF conversion rate improved to 64%
- Average price growth of 14% in Student Placement
- Maintained student NPS above 70, reflecting positive student experience
- Strong focus on technology and innovation for efficiency and user experience
- Positioned to expand market share despite challenging conditions
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$616 |
Imricor Releases FY24 Results
|
27 Feb 2025 8:07AM |
$1.460 |
$1.920 |
risen by
31.51%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- First module submitted and returned by US FDA with no deficiencies
- NorthStar submitted for CE Mark approval in Europe
- First MRI guided ablation on US soil performed at Johns Hopkins as part of VISABL-AFL
- Saudi FDA approval received, registration completed in Qatar opening Middle East
- CE Mark approval of MR Vision diagnostic catheter
- VISABL-AFL global pivotal trial commences enrolment in France, US and Switzerland
- Global rollout underway with new site activations in France, Netherlands, Croatia and Switzerland
- Installation complete in Hungary, first procedures being scheduled
- First purchase orders received from Qatar initiating expansion into Middle East
- Group revenue of US$959k + 56% on prior year
- Operating costs well contained down 1% to $17.3m including R&D investment
- Strong balance sheet US$15.7m cash in place to fund major milestones in 2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
